This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
There are new treatment options on the horizon that may help reduce the number of traditional surgeries while increasing effectiveness.
Matrix metalloproteinases (or MMPs) may sound like something out of a sci-fi story, but they’re a real-life family of enzymes—the metzincin superfamily—that thrive inside the human body.
Researchers are developing a new type of glasses that contain a prism that will redirect the sight of a person with limited peripheral vision.
“What motivates me is the very real possibility of discovering something in my laboratory that can allow patients to see to see much better, for much longer periods of their life, and maybe even reverse blindness.”
Glaucoma causes damage to the optic nerve, which can result in an eventual loss of vision.
Glaucoma doesn’t typically damage RPE cells, but thanks to advances in stem cell research, it looks like RPE cells may play a crucial role in finding a cure to the degenerative disease.
No one can predict the next big breakthrough in glaucoma treatment, but one thing is certain: A whole lot of experts are searching for ways to make the future better.
Eye injury does not have to lead to traumatic glaucoma if the patient has regular eye examinations with an eye doctor who knows what to look for.
In an attempt to demonstrate that low vision patients have good potential for overcoming vision loss, researchers undertook a study and presented their findings.
With exciting new biomarkers on the horizon, this is a good time to learn more about what they are and how they’ll ultimately help find a cure for glaucoma.
Data published in October 2016 shows there is a successful, safe, routine surgical procedure that has been restoring eyesight for ages, and it may be the answer to treating primary closed-angle glaucoma (PCAG).
Catalyst for a Cure researchers have been taking necessary steps to move their studies from the laboratory to the clinic.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
